A compound having a structure selected from the group consisting of: in which each x is independently (1) or (2) Y is selected from the group consisting of OSN-(C(R7)z)s-where each R7 IS independently as previously defined fir R1, each z is independently 1-2, and s is 1-3CH= -CH=CH or Y1CH2_where Y1 is O, N, or S and the dotted lines are optional double bonds, with the pviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsaturated, and that if Y is O,N or S, the ring including Y contains at least one said double bond, said compound further having selective agonist activity at the α2B or α2B/α2C adrenergic receptor subtype(s) over the α2A adrenergic receptor subtype, and all pharmacologically acceptable salts, esters, stereoisomers and racemic mixtures thereof.Linvention concerne des méthodes et des composés permettant de traiter des états comprenant la douleur, la douleur particulièrement chronique, le glaucome ou la pression intra-oculaire élevée, en entraînant des effets secondaires sédatifs et cardiovasculaires réduits. Linvention concerne en outre des méthodes de production et dutilisation desdits composés.
